Aim
To change the continuous subcutaneous insulin infusion (CSII) system could be an opportunity to improve CSII management; however, security issues could appear. The aim is to report the feasibility and safety of the simultaneous transition from one CSII system to another in a specific program in a group of Type 1 Diabetes (T1D) patients.

Methods
The program consisted of 3 sessions: 1) Group system start-up training session. 2) Call from medical staff 72h after session 1. 3) Group training session regarding the use of therapy management software. Demographic data, HbA1c, pump use and settings, hypoglycaemia awareness and retrospective continuous glucose monitoring (rCGM) data were collected previously and are being collected at 4 months from the switch. During these 4 months clinical events, technical issues, and training reinforcement incidents were registered.

Results
Insulin pump device has been changed in thirty-three T1D patients during June-July 2018. Baseline characteristics and insulin pump settings/use are shown in tables 1 and 2 respectively. Baseline, the CGM mean blood glucose is 156.1±60.6 mg/dL with 62.1% of time-in-range. The analysis about clinical or technical issues during 4 months follow-up as well as clinical and pump management is currently being carried out. 

Conclusions
Switching to a new insulin pump in a group of patients is a challenge and an opportunity to improve the management of the therapy. The outcomes of the process need to be evaluated.

ANALYSIS OF INSULIN PUMP DEVICE REPLACEMENT IN A GROUP OF TYPE 1 DIABETES PATIENTS IN A STRUCTURED PROGRAM